A phase II study of thalidomide in patients with brain metastases from malignant melanoma

Lene Vestermark, Susanne Larsen, Birgit Lindeløv, Lars Bastholt

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Introduction. Brain metastases develop in nearly half of the patients with advanced melanoma and in 15 to 20% of these patients CNS is the first site of relapse. Overall median survival is short, ranging from 2 to 4 months. Thalidomide has antiangiogenic and immunomodulatory effects. Results obtained in prior trials indicate that Thalidomide acts as a cytostatic agent in metastatic melanoma. We evaluated single agent antitumour activity and toxicity of Thalidomide in a phase II setting in patients with brain metastases associated with metastatic melanoma. Material and methods. Patients with measurable metastatic melanoma in progression and with PS
Original languageEnglish
JournalActa Oncologica
Pages (from-to)1-5
Number of pages4
ISSN0284-186X
DOIs
Publication statusPublished - 6. Feb 2008

Fingerprint

Melanoma

Cite this

@article{f73165c051d011ddb1a1000ea68e967b,
title = "A phase II study of thalidomide in patients with brain metastases from malignant melanoma",
abstract = "Introduction. Brain metastases develop in nearly half of the patients with advanced melanoma and in 15 to 20{\%} of these patients CNS is the first site of relapse. Overall median survival is short, ranging from 2 to 4 months. Thalidomide has antiangiogenic and immunomodulatory effects. Results obtained in prior trials indicate that Thalidomide acts as a cytostatic agent in metastatic melanoma. We evaluated single agent antitumour activity and toxicity of Thalidomide in a phase II setting in patients with brain metastases associated with metastatic melanoma. Material and methods. Patients with measurable metastatic melanoma in progression and with PS",
author = "Lene Vestermark and Susanne Larsen and Birgit Lindel{\o}v and Lars Bastholt",
year = "2008",
month = "2",
day = "6",
doi = "10.1080/02841860801918521",
language = "English",
pages = "1--5",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Taylor & Francis",

}

A phase II study of thalidomide in patients with brain metastases from malignant melanoma. / Vestermark, Lene; Larsen, Susanne; Lindeløv, Birgit; Bastholt, Lars.

In: Acta Oncologica, 06.02.2008, p. 1-5.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - A phase II study of thalidomide in patients with brain metastases from malignant melanoma

AU - Vestermark, Lene

AU - Larsen, Susanne

AU - Lindeløv, Birgit

AU - Bastholt, Lars

PY - 2008/2/6

Y1 - 2008/2/6

N2 - Introduction. Brain metastases develop in nearly half of the patients with advanced melanoma and in 15 to 20% of these patients CNS is the first site of relapse. Overall median survival is short, ranging from 2 to 4 months. Thalidomide has antiangiogenic and immunomodulatory effects. Results obtained in prior trials indicate that Thalidomide acts as a cytostatic agent in metastatic melanoma. We evaluated single agent antitumour activity and toxicity of Thalidomide in a phase II setting in patients with brain metastases associated with metastatic melanoma. Material and methods. Patients with measurable metastatic melanoma in progression and with PS

AB - Introduction. Brain metastases develop in nearly half of the patients with advanced melanoma and in 15 to 20% of these patients CNS is the first site of relapse. Overall median survival is short, ranging from 2 to 4 months. Thalidomide has antiangiogenic and immunomodulatory effects. Results obtained in prior trials indicate that Thalidomide acts as a cytostatic agent in metastatic melanoma. We evaluated single agent antitumour activity and toxicity of Thalidomide in a phase II setting in patients with brain metastases associated with metastatic melanoma. Material and methods. Patients with measurable metastatic melanoma in progression and with PS

U2 - 10.1080/02841860801918521

DO - 10.1080/02841860801918521

M3 - Journal article

SP - 1

EP - 5

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

ER -